首页> 外文期刊>Oman Journal of Ophthalmology >Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
【24h】

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes

机译:瑞巴派特2%眼药水治疗干眼症的功效

获取原文
       

摘要

AIM: The aim of this study is to evaluate the efficacy of 2% rebamipide ophthalmic solution on the tear functions and ocular surface status in patients with dry eyes. MATERIALS AND METHODS: A prospective study was carried out on forty eyes of patients having signs and symptoms of dry eye. Two percent rebamipide ophthalmic solution was applied four times a day for a period of 4 weeks. Patients were evaluated on the basis of dry eye-related symptom score, tear film break-up time (TFBUT), tear meniscus height, fluorescein ocular surface staining score (FOSS), and the Schirmer's test at the end of 2, 4, 6, and 12 weeks and their values were compared with the baseline. RESULTS: Significant improvement was noted in the mean dry eye-related symptom score, TBUT, and the FOSS values from the baseline at the end of 2, 4, 8, and 12 weeks. The values of tear meniscus height and Schirmer's test were improved at the end of 8 weeks but were not statistically significant. CONCLUSION: Nearly 2% rebamipide ophthalmic solution provided relief in the symptoms of patients having dry eyes. It also prevented further ocular surface damage and aided in stabilizing the tear film.
机译:目的:本研究的目的是评估2%瑞巴派特滴眼液对干眼患者的泪液功能和眼表状态的疗效。材料与方法:对有干眼症状和体征的四十只眼睛的患者进行了一项前瞻性研究。每天四次使用2%的瑞巴派特眼用溶液,持续4周。根据与干眼相关的症状评分,泪膜破裂时间(TFBUT),泪液半月板高度,荧光素眼表染色评分(FOSS)以及2、4、6末尾的Schirmer检验对患者进行评估,并将其12周的值与基线进行比较。结果:在第2、4、8和12周结束时,平均干眼相关症状评分,TBUT和与基线相比的FOSS值显着改善。泪液半月板高度和Schirmer检验的值在8周结束时有所改善,但无统计学意义。结论:将近2%瑞巴派特滴眼液可缓解干眼患者的症状。它还防止了进一步的眼表损伤,并有助于稳定泪膜。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号